Set and setting in psychedelic experiences

Set and setting in psychedelic experiences describes how a session is shaped not only by a drug’s pharmacological action but also by the participant’s state of mind and the environment in which the drug is taken. In the clinical history recounted here, the idea emerges from a practical problem: the same treatment that appeared effective in a supportive setting produced frightening experiences and weaker results when researchers tried to isolate the drug in emotionally neutral conditions. The concept therefore bears on both therapeutic practice and the possibility of testing psychedelic treatments by conventional scientific methods.

Origins in Alcohol Treatment

At the Weyburn hospital in Saskatchewan, Humphry Osmond and Abram Hoffer learned from volunteers that the conditions surrounding an LSD session could strongly affect its character. They came to value the presence of an engaged, empathetic therapist, ideally one with personal experience of LSD, as a way to reduce the chance of a difficult session. They also began to suspect that some reactions labeled psychotic might be products of the clinical situation itself: a metaphorical white room, a white-coated clinician, and an impersonal encounter. Although the phrase set and setting was not yet in use, their observations anticipated the principle later associated with Timothy Leary’s work at Harvard.

By the end of the 1950s, LSD was widely regarded in North America as a possible miracle cure for alcohol addiction, and the Saskatchewan provincial government helped make LSD therapy a standard treatment option for alcoholics in the province. That apparent success became a point of dispute when the Addiction Research Foundation in Toronto attempted a more tightly controlled replication in the early 1960s. Seeking to separate the drug’s effects from other influences, clinicians placed participants in neutral rooms, avoided engaging with them except to administer an extensive questionnaire, and sometimes restrained or blindfolded them. The results did not match those from Saskatchewan; more than a few participants endured terrifying experiences. Critics could point to the weaker outcome under rigorous controls, while supporters could point to the removal of the attentive setting they believed was essential. The contrast made the disputed variable impossible to ignore.

A Challenge to Experimental Control

The concept complicates a basic premise of conventional drug trials: that researchers can isolate a medicine’s effect by holding other variables constant. In psychedelic studies, participants can often tell whether they received psilocybin or a placebo, as can their guides, making blinding difficult. Meanwhile, the participant’s expectations, the treatment environment, and the presence and conduct of therapists may all shape the experience. If a drug’s effects depend partly on these conditions, then separating its chemical action from the context of administration may not produce a clean measure of what the treatment does in practice.

A further complication is that treatment itself can organize the participant’s expectations. In psychedelic-assisted therapy, the intention to change a habit can be reinforced in preparatory meetings and in integration afterward. The therapist helps shape the set of the session, using the guide’s authority and the session’s structure to direct the drug’s suggestive potential toward a therapeutic purpose. On this account, treatment is not simply the administration of a substance: the preparation, experience, and subsequent interpretation belong to the therapeutic process. The implication is not that the drug is irrelevant, but that its effects cannot be understood apart from the human and situational conditions in which it is used.

Clinical Evidence and Its Limits

Research findings illustrate why context matters without resolving the question of how much it matters. In the New York University and Johns Hopkins cancer trials, about 80 percent of participants showed clinically significant reductions in anxiety and depression, with effects lasting at least six months. Across both trials, the reported intensity of the mystical experience closely correlated with the degree of symptom reduction. This association makes the character of the session relevant to evaluating outcomes, but a correlation does not by itself establish that the experience caused the improvement or identify which parts of the treatment produced it.

The depression feasibility study directed by Robin Carhart-Harris in David Nutt’s lab at Imperial College makes the limits of early evidence equally visible. Its first group consisted of twelve people with treatment-resistant depression, all of whom knew they were receiving psilocybin because the study had no control group. After a week, all showed improvement and two-thirds were depression-free; seven still showed substantial benefit after three months. When the study expanded to twenty participants, six remained in remission after six months, while the others had relapsed to varying degrees. The study found rapid benefits and no adverse events in this group, but its small scale and lack of randomization meant that it could not settle the treatment’s efficacy. The same contextual factors that may contribute to therapeutic change also make it harder to attribute that change to a single cause.

Earlier research provides a caution against mistaking striking results for secure proof. Timothy Leary reported that ten months after release, 25 percent of participants in the Concord Prison Experiment had returned to jail, compared with 80 percent of the control group. Decades later, Rick Doblin’s subject-by-subject reconstruction concluded that Leary had exaggerated the results and that there was no statistically significant difference in recidivism. The case does not establish that context is ineffective; it shows instead how methodological weakness can make a dramatic treatment claim unreliable. Small samples, selection of likely responders, unusually attentive therapists, and the strength of expectation effects are all reasons to treat early positive findings as promising signals rather than definitive demonstrations of cure.

Therapy Between Science and Ritual

The importance assigned to set and setting also unsettles the boundary between medical treatment and spiritual or ritual practice. Charles Grob described psychedelic therapy as applied mysticism, a characterization that places it uneasily within a psychiatry increasingly committed to biochemical explanations. Franz Vollenweider regarded mysticism as an interesting shamanic concept rather than a medical one, while Grob argued that strict scientific method alone might not be enough to design optimal studies. He called for attention to the shamanic model, in which a guide deliberately organizes the conditions of an experience and uses its suggestibility toward a purpose.

This tension links the contemporary clinical debate to an earlier divide in psychedelic research. Al Hubbard’s Commission for the Study of Creative Imagination, formed in 1955, signaled an effort to take psychedelic work beyond medicine’s focus on the ill. Sidney Cohen resigned from its board in 1957, while Hubbard said his interest was moving toward something beyond empirical manipulation. The commission’s uncertain institutional substance did not erase its significance as a sign of diverging medical and spiritual aims. In later clinical arguments, the same divide reappears as a methodological question: if the treatment’s setting and guiding relationship are active ingredients, they cannot simply be removed as distractions without changing the treatment being studied.

The renewed recognition of psychedelic-assisted psychotherapy therefore depends on holding two demands together. Researchers need rigor, careful attention to safety, and restraint in interpreting small or uncontrolled studies. At the same time, a design that treats the drug as an isolated variable may fail to represent the therapeutic process that clinicians intend to evaluate. Set and setting names that unresolved problem: context is a potential source of bias in causal inference, but it is also part of the conditions under which a psychedelic experience can become therapeutic.